Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CBLL
stocks logo

CBLL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 22.40 USD with a low forecast of 17.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 22.40 USD with a low forecast of 17.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.150
sliders
Low
17.00
Averages
22.40
High
30.00
Current: 19.150
sliders
Low
17.00
Averages
22.40
High
30.00
JPMorgan
Overweight
to
Buy
downgrade
$21 -> $17
2025-11-05
Reason
JPMorgan
Price Target
$21 -> $17
2025-11-05
downgrade
Overweight
to
Buy
Reason
JPMorgan lowered the firm's price target on Ceribell to $17 from $21 and keeps an Overweight rating on the shares. The company reported another good "beat-and-raise" with tailwinds heading into 2026, the analyst tells investors in a research note.
TD Cowen
Buy
downgrade
$36 -> $20
2025-11-05
Reason
TD Cowen
Price Target
$36 -> $20
2025-11-05
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Ceribell to $20 from $36 and keeps a Buy rating on the shares. The firm updated its model following a solid quarter and guidance that reflects continued adoption.
Raymond James
Jayson Bedford
Strong Buy
initiated
$19
2025-10-20
Reason
Raymond James
Jayson Bedford
Price Target
$19
2025-10-20
initiated
Strong Buy
Reason
Raymond James analyst Jayson Bedford initiated coverage of Ceribell with a Strong Buy rating and $19 price target. Ceribell is pioneering the rapid EEG market with differentiated technology that improves outcomes for patients and providers, says the analyst, who sees "consistent execution" as "disconnected from stock price performance" with shares down 51% year-to-date. The firm says its rating is "not a call" on Q3 results, but its belief that the valuation does not match the financial profile and "gives little credit for current (and pipeline) opportunities."
BTIG
Marie Thibault
initiated
$30
2025-06-24
Reason
BTIG
Marie Thibault
Price Target
$30
2025-06-24
initiated
Reason
Ladenburg Thalmann
Jeff Cohen
Strong Buy
Initiates
$32
2025-04-04
Reason
Ladenburg Thalmann
Jeff Cohen
Price Target
$32
2025-04-04
Initiates
Strong Buy
Reason
Ladenburg initiated coverage of Ceribell with a Buy rating and $32 price target. The company has a first-mover advantage in scaling rapid electroencephalography technology for acute neurological care, the analyst tells investors in a research note.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$33
2025-02-26
Reason
Canaccord Genuity
William Plovanic
Price Target
$33
2025-02-26
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ceribell Inc (CBLL.O) is -12.62, compared to its 5-year average forward P/E of -12.02. For a more detailed relative valuation and DCF analysis to assess Ceribell Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.02
Current PE
-12.62
Overvalued PE
-6.52
Undervalued PE
-17.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.06
Undervalued EV/EBITDA
-20.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.41
Current PS
0.00
Overvalued PS
10.87
Undervalued PS
3.94
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CBLL News & Events

Events Timeline

(ET)
2025-11-24
08:02:19
Ceribell Secures FDA 510(k) Approval for Clarity Algorithm
select
2025-11-04 (ET)
2025-11-04
17:01:07
Ceribell increases FY25 revenue forecast to $87M-$89M, up from $85M-$88M
select
2025-11-04
16:57:24
Ceribell Announces Q3 EPS of 37 Cents, Below Consensus Estimate of 41 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-24Newsfilter
CeriBell Receives FDA Clearance for Next-Gen Neonatal Seizure Detection Technology
  • FDA Clearance: CeriBell, Inc. announced that its next-generation ClarityⓇ algorithm has received FDA 510(k) clearance, making it the first AI-powered EEG technology capable of detecting electrographic seizures across all ages. This approval significantly enhances early detection capabilities for neonatal seizures, addressing urgent needs in NICU care.
  • Market Demand: Research indicates that approximately 90% of neonatal seizures go undetected, and CeriBell's technology aims to address this critical gap. By enabling real-time monitoring, it can identify seizure activity promptly, reducing mortality and long-term disability risks for high-risk newborns.
  • Clinical Validation: The FDA clearance was supported by EEG data from over 700 patients, representing the largest validation dataset for a neonatal seizure detection system. This data reinforces the effectiveness of the CeriBell system in clinical applications, enhancing its competitive position in the market.
  • Technological Advantage: The CeriBell system combines proprietary algorithms with specialized hardware to detect non-convulsive seizures in real time, facilitating rapid diagnosis and treatment. This innovation is set to improve the quality of neonatal care, ensuring timely seizure detection for every newborn.
[object Object]
Preview
9.5
11-09NASDAQ.COM
CeriBell (CBLL) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
6.0
11-06Benzinga
JP Morgan Keeps Overweight Rating on CeriBell, Adjusts Price Target to $17

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders succeed in the stock market with accurate intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ceribell Inc (CBLL) stock price today?

The current price of CBLL is 19.15 USD — it has increased 6.39 % in the last trading day.

arrow icon

What is Ceribell Inc (CBLL)'s business?

CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.

arrow icon

What is the price predicton of CBLL Stock?

Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 22.40 USD with a low forecast of 17.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ceribell Inc (CBLL)'s revenue for the last quarter?

Ceribell Inc revenue for the last quarter amounts to 22.59M USD, increased 31.37 % YoY.

arrow icon

What is Ceribell Inc (CBLL)'s earnings per share (EPS) for the last quarter?

Ceribell Inc. EPS for the last quarter amounts to -0.37 USD, increased 19.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ceribell Inc (CBLL)'s fundamentals?

The market is revising Upward the revenue expectations for CeriBell, Inc. (CBLL) for FY2025, with the revenue forecasts being adjusted by 1.53% over the past three months. During the same period, the stock price has changed by 62.29%.
arrow icon

How many employees does Ceribell Inc (CBLL). have?

Ceribell Inc (CBLL) has 281 emplpoyees as of December 05 2025.

arrow icon

What is Ceribell Inc (CBLL) market cap?

Today CBLL has the market capitalization of 710.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free